Lead Product(s) : Guadecitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neither study met the primary endpoint of statistically significant (p <0.05) improvement in overall survival (OS) compared with the control arm of physicians’ choice of alternative therapy.
Product Name : SGI-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Guadecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable